Press Releases

BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London

HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 17, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting Thursday, May 19 th, at the 11th World Stem Cells & Regenerative Medicine Congress in London, UK. Mr. Lebovits will moderate a round table session on Brainstorm's NurOwn® proprietary technology and its potential to introduce a groundbreaking treatment for Amyotrophic lateral sclerosis (ALS).

BrainStorm Cell Therapeutics

World Stem Cells & Regenerative Medicine Congress
Date: Thursday May 19
Time: 11.25 AM BST - British Summer Time (06.25 AM EDT)
Location: Business Design Centre, London, UK

World Stem Cells & Regenerative Medicine Congress

The "World Stem Cells & Regenerative Medicine Congress", taking place May 18 th – 20th, is an annual international conference, which brings together key industry players and senior executives within the space of regenerative medicine. The conference is mainly focused on developing the commercial aspects of stem cells, with the addition of innovation within regenerative medicine, notably tissue engineering, and also in the growing field of stem cells.

About BrainStorm Cell Therapeutics Inc .

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188

Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds